期刊
CELLS
卷 11, 期 24, 页码 -出版社
MDPI
DOI: 10.3390/cells11244114
关键词
FSHD; epigenetics; DNA methylation; neuromuscular diseases; biomarker; machine learning
类别
资金
- FSHD Society Research Grant [Winter2021-0992658837]
The study presents a protocol for methylation analysis combined with Machine Learning algorithms to classify patients with Facio-Scapulo-Humeral Dystrophy (FSHD). The results show significantly reduced methylation levels in FSHD patients compared to healthy controls. A Machine Learning model was developed to accurately classify FSHD patients, providing further evidence of DNA methylation as a powerful disease biomarker.
The study describes a protocol for methylation analysis integrated with Machine Learning (ML) algorithms developed to classify Facio-Scapulo-Humeral Dystrophy (FSHD) subjects. The DNA methylation levels of two D4Z4 regions (DR1 and DUX4-PAS) were assessed by an in-house protocol based on bisulfite sequencing and capillary electrophoresis, followed by statistical and ML analyses. The study involved two independent cohorts, namely a training group of 133 patients with clinical signs of FSHD and 150 healthy controls (CTRL) and a testing set of 27 FSHD patients and 25 CTRL. As expected, FSHD patients showed significantly reduced methylation levels compared to CTRL. We utilized single CpG sites to develop a ML pipeline able to discriminate FSHD subjects. The model identified four CpGs sites as the most relevant for the discrimination of FSHD subjects and showed high metrics values (accuracy: 0.94, sensitivity: 0.93, specificity: 0.96). Two additional models were developed to differentiate patients with lower D4Z4 size and patients who might carry pathogenic variants in FSHD genes, respectively. Overall, the present model enables an accurate classification of FSHD patients, providing additional evidence for DNA methylation as a powerful disease biomarker that could be employed for prioritizing subjects to be tested for FSHD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据